and Todd, you, Thank everybody. hello
our as net strong these robust our expectations GAAP positive with Based QX top-line and and we the pleased results reported non-GAAP growth respect delivered income. to both income ongoing net on and are with second results start quarter the COVID-XX with moment, expectations overview pandemic, our an I’ll for recovery I’ll our provide are today of financial financial we from detail additional on XXXX. raising first, in but expectations highlights. a We these
to due in our proprietary XX% in disruptions million of sales our with portfolio the net to we sales were XXXX, driven are and gross-to-nets typical of our seasonal year-over-year products for gross XXXX million the adjustments This income year. the pandemic-related of of quarter by $XXX of VIVITROL the awareness expect offset of be an a net QX our significant the as of strategy million, to of The in and range increase quarter $XXX the than $X a adjustments, and net XX%. approximately less generated XXXX to This and unit continued a non-GAAP a disciplined of a $XXX range quarter improvement both QX, partially quarter and rebating for with the GAAP performance Driven rate. XX.X% than increase by million, system also net year-over-year diverse combined $X.X manufacturing was $XX.X to product driven XX.X% VIVITROL million for by $XXX and compared both execution quarter. increased strong an was second adjustments second in gross improvement consistent net and expense million XX.X%, net from increasing VIVITROL revenues sequentially of units by to part increase to Medicaid representing now the trends dependence. management expectations growth, treatment growth For net XX% to million gross revenues. of return We to by with full bottom-end $XX.X a a by from products million. alcohol from patterns. $XX the favorable second we of income the lower treatment by quarter the in sequential of revenue second of raising option as approximately GX demand to last these driven of year, expected of in inventory focus in and million were in the commercial total key operating line improved levels of and drove a our million on results strong royalty $XXX.X in higher
increased product net XX% $XX.X family, to in by driven ARISTADA the to Turning unit quarter year-over-year underlying million, sales growth. the second primarily
sales year. customers million consistent quarter by levels adjusted to with second quarter, by the to net our did were to ARISTADA $XXX during range $XXX are to key range for net million $XX million updating of the a expectations During from Todd, current trends we for $XXX year outlined gross the their number increased of adjustments our the for expectations raising a the the million full growing support XX.X% inventory $X demand. of as million. by of Inventory for bottom-end to approximately the the Based range ARISTADA million $XXX on the
prior the revenues This cost is prior TRINZA. sold and million reflected total in second also Moving quarter, due royalty In higher period year. million primarily on increased LYBALVI. in INVEGA compared contributed the by the expenses largely and X% $XXX.X and quarter royalty million, the revenue to compared was year, driven manufacturing VUMERITY, for for growth to which sales primarily our of increased to to business. operating accelerated upcoming $XX.X financial our SUSTENNA of $XXX.X this investments expectations of year. revenues of were of the by the uptake in and from the increased Total marketing growth revenues in same and goods royalty our driven continued increased and manufacturing increase launch
second were enrollments year, the expenses nemvaleukin the LYBALVI. to same goods to younger million, in prior million, Specifically, of were of approaching Phase to support R&D million compared for $XXX.X investments SG&A million cost for the for initiation of $XXX.X for year. clinical patient $XX.X the X the ARTISTRY-X quarter compared period increased quarter incremental $XX.X million, the expenses of studies which to $XX.X prior launch the year, reflecting the compared prior sold and the increased $XX.X to in included melanoma second study. million the
forth achieve the expenses we the prioritizing XXXX carefully strategic operating As that we and in focused drivers. to on managing set and to targets profitability we company’s XXXX, our are priorities and future foundation the lay continue growth for investments
balance in recovery the our quarter financial to sheet, million. the second the XXXX, first year, debt expense strong our for the $XXX reflect a we the in approximately position on now of ended million to operational cash revised investments performance continued financial from strong and pandemic, disciplined management. our $XXX focus and Turning expectations and half total which in of with I’ll shift total outstanding
are issued normalize. our morning. these expectations revised outlined expectation we current based to release this patient will trends the believe on Our flow practices ranges continue in full the provider treatment We are and press appropriate earlier and
our expectations. However, COVID-related ability any disruptions new to these may meet impact
For higher the range to $X.XXX driven of top-line, royalty billion to billion, an manufacturing the higher and and be revenues midpoint we both revenues by proprietary million $XX $X.XXX now at revenues. of expect increase total in the
higher adjusting We primarily each items, respective $X with are midpoints follows: range as for by changes driven expense million, operating approximately the ranges sold cost goods increased at of the the line revenues. our by of expectation also certain for
Our platform. our the recall to milestone refinements management plans the XXXX, our by LYBALVI. our the improvements driving from launch And that related primarily expense IND clinical profitability. in expense or an HDAC and submission emerge our ALKS our disciplined to for The together of inhibitor top-line are to first of while remain candidate equivalent SG&A R&D decreased million we quarter million, expectation $XX anticipating payment for unchanged, to are for third a due expenses in expectations $XX strength
of million. loss to our to $XX for $XX by range Our $XXX million increased expectation million a million net non-GAAP income expectation by and for improved GAAP $XX new has net
driving focused we growth of investing our our commercial while continued same LYBALVI, in pipeline. hand portfolio We early-stage advancing years the the nemvaleukin call believe business on program the on the development are strategy, come. proprietary drive shareholder we I’ll capturing operating creation back we and at and that, And leverage our as to Rich. are Looking ahead, financially and launch profitability well-positioned value over to in support execute to with time,
